Načítá se...
Not All Immune Checkpoints Are Created Equal
Antibodies that block T cell inhibition via the immune checkpoints CTLA-4 and PD-1 have revolutionized cancer therapy during the last 15 years. T cells express additional inhibitory surface receptors that are considered to have potential as targets in cancer immunotherapy. Antibodies against LAG-3 a...
Uloženo v:
| Vydáno v: | Front Immunol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6127213/ https://ncbi.nlm.nih.gov/pubmed/30233564 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.01909 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|